Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021-Reference-Cited by-同舟云学术

Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021

Published:2021-08-19 Issue:33 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Lee Eunju¹^ORCID,Lee Yeon-kyeong¹^ORCID,Kim Tae Eun¹^ORCID,Hwang Insob¹^ORCID,Jung Yeon Haw²^ORCID,Lee Hye Ryeon²^ORCID,Song Jeongsuk¹^ORCID,Park Youngjoon²^ORCID,Cho Enhi³^ORCID,Lee Yeon-Kyeng¹^ORCID

Affiliation:

1. Adverse Event Management Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea

2. Adverse Event Investigation Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea

3. Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea

Abstract

The South Korea mass vaccination programme administered 3.8 million doses of COVID-19 vaccinations between 26 February and 30 April 2021. After 173 suspected anaphylaxis reports to the nationwide monitoring system for adverse events following immunisation, 44 anaphylaxis cases were confirmed using Brighton Collaboration case definitions. The rates per million doses were 18.2 cases and 6.2 cases for Vaxzevria and Comirnaty, respectively. Median time of onset was 14 min after vaccination and most cases had recovered at the time of review.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference10 articles.

1. Law B. SO2- D2.5.2.1 AESI case definition companion guide for 1st Tier AESI – Anaphylaxis. Safety Platform for Emergency vACcines. Ponce de Leon: The Task Force for Global Health; 2021. Available from: https://brightoncollaboration.us/wp-content/uploads/2021/03/SPEAC_D2.5.2.1_Anaphylaxis-Case-Definition-Companion-Guide_V1.0-12070-1.pdf

2. Korea Disease Control and Prevention Agency (KDCA). Update on COVID-19 and COVID-19 vaccination. Press release. Cheongju-si: KDCA; 12 Apr 2021. Korean. Available from: http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=5162&contSeq=5162&board_id=312&gubun=ALL

3. European Medicines Agency (EMA). Press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) and thromboembolic events. Press release. Amsterdam: EMA; 7 Apr 2021. Available from: https://www.ema.europa.eu/en/events/press-briefing-conclusion-assessment-pharmacovigilance-risk-assessment-committee-prac-vaxzevria

4. Korea Disease Control and Prevention Agency (KDCA). Adverse events following COVID-19 immunization management guidelines. Cheongju-si: KDCA; 2021. Korean. Available from: https://ncv.kdca.go.kr/board.es?mid=a12101000000&bid=0031#content

5. Treatment and management of anaphylaxis.;Jeong;J of the Korea,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea;Clinical and Experimental Pediatrics;2023-10-15

2. Expertise as a Response to Limited Multilateralism: The Case of South Korea's Vaccine Procurement Task Force for COVID-19 Vaccines amid Unequal Access via the COVAX Facility;Journal of Health Politics, Policy and Law;2023-07-31

3. COVID-19, post-acute COVID-19 syndrome (PACS, “long COVID”) and post-COVID-19 vaccination syndrome (PCVS, “post-COVIDvac-syndrome”): Similarities and differences;Pathology - Research and Practice;2023-06

4. Adverse event reports of anaphylaxis after Comirnaty and Vaxzevria COVID‐19 vaccinations, Western Australia, 22 February to 30 June 2021;Internal Medicine Journal;2023-02

5. Relationship Between Coronavirus Disease 2019 Vaccination Rates and Rare But Potentially Fatal Adverse Events: A Regression Discontinuity Analysis of Western Countries;Journal of Korean Medical Science;2023